I. G. Paliy, I. G. Reznichenko

The high effectiveness of intestinal adsorbent (enterosorbent) Enterosgel as a detoxifying agent in infectious and inflammatory diseases is associated with its ability to adsorb MWM and pathogenic micro-organisms, thereby positively influencing the cellular and humoral immunity. Enterosgel contributes to enhancing the functional activity of neutrophilic granulocytes to the level of subcompensation. Enterosorption with Enterosgel contributes to restoring the functional activity of T lymphocytes and B lymphocytes.

I.V. Bagdasarova, Institute of Nephrology AMS of Ukraine, O.I. Osadchaya, А.М. Boyarskaya, Institute of Hematology and Transfusiology AMS of Ukraine, B.S. Sheyman, N.А. Voloshina, L.I. Medved Institute of Ecohygiene and Toxicology, the Ministry of Health of Ukraine.

The use of enterosorption with Enterosgel medication in combination therapy of children with acute pyelonephritis reduces the toxic load on the neutrophilic granulocytes and contributes to the preservation of functional activity of the given cells at subcompensated level, reducing the risk of generalization of infection and the development of associated complications.

The use of Enterosgel medication in combination therapy of children with acute glomerulonephritis promotes preservation of the functional activity of monocytes and optimization of their participation in the mechanisms of antigen presentation to immune cells, which reduces the risk of autoimmune complications.

Fedorova O.V., Fedulova E.N., Tutina O.A., Korkotashvili L.V.

CONCLUSIONS

IBD in children is accompanied by the development of endogenous intoxication, manifestation of which is conditioned by the severity of the process and dependent on the nature of intestinal lesion.

Enterosorption is an effective and safe method of sorption detoxification in the combination treatment of IBD in children, since it reduces the toxic load on the detoxification system of the body and the risk of developing infectious and autoimmune complications.

Enterosgel is the adsorbent of choice since it has high effectiveness and safety in young children, significant cytoprotective effect, convenient pharmaceutical form, and can be used in a long-term repeated course. 

Fedorova O.V., Fedulova E.N., Tutina O.A., Shumilova O.

Discussion/Conclusion
A high clinical efficiency of Enterosgel preparation has been determined and its positive effect on the intestinal mucosa condition, digestion and absorption processes, the composition of small and large intestine-related microflora. The immunomodulative effect has been identified as conditioned by the normalization of eubiosis and the decreased inflammation activity in the intestinal mucosa. 

Fedorova O.V., Fedulova E.N., Tutina O.A.

Consequently Enterosgel creates comfortable conditions for development of the normal microflora and improvement of the microbiological landscape of the intestine. Cytoprotective properties of the preparation are stipulated by restoration of the intestinal barrier accompanied by increase of sIgA secreted by cells of the mucous membrane of the intestine, restoration of the structure of the microcirculatory race and positive morphologic dynamics.
Apparent clinic efficiency with the distinct cytoprotective effect and comfortable pharmaceutical form enable to recommend Enterosgel for wide application with children with IID for the purpose of sorption efferent therapy. 

Chernikhova E.A., Anikhovskaya I.A., Gataullin Yu.K., Zakirova D.Z., Ivanov V.B., Saveliev A.A., Yakovlev M.Yu.

Conclusions
Method of intestinal adsorption (enterosorption) can be used as a means of CEA elimination. Monotherapy with Enterosgel, the intestinal adsorbent of new generation, reduces the average LPS concentration in the general circulation by 56% and is capable to eliminate CEA in every fourth patient with chronic inflammatory diseases. 

Bezlyuda N.P., Baranyuk A.P.

Novel intestinal and topical adsorbent drugs with detoxifying effect (studies were conducted in 1980-1990 by order of Main Military Clinical Hospital of the Ministry of Defense of Ukraine) were widely evaluated in military medical facilities. The Military Hospital of Kyiv (nowadays the Main Military Clinical Hospital of the Ministry of Defense of Ukraine) participated in the medical and biological evaluation of novel drugs from the beginning of their development (V.N. Fadeev, F.G. Novikov, N.P. Bezlyuda).